retatrutide type 2 diabetes trial results Effects of on body composition in people with diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised Retatrutide UK Guide: Key Facts

The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks

Blood Sugar Regulation and Insulin Sensitivity: These medications help: Stimulate insulin secretion Reduce insulin resistance Restore healthy blood sugar levels This supports not only diabetes management but also overall metabolic health and reduces risks associated with conditions like heart disease and metabolic syndrome

What if I miss a weekly injection

Apovian, M.D., DABOM, co-director of the Center for Weight Management and Wellness at Brigham and Womens Hospital and faculty member at Harvard Medical School